Difference between revisions of "Teclistamab (Tecvayli)"
Jump to navigation
Jump to search
m |
m |
||
Line 3: | Line 3: | ||
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
+ | |||
+ | ==Toxicity management== | ||
+ | *[https://tecvaylirems.com/#Main REMS program] | ||
==Diseases for which it is established== | ==Diseases for which it is established== | ||
Line 25: | Line 28: | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
− | + | [[Category:REMS program]] | |
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] |
Revision as of 17:14, 25 December 2022
General information
Class/mechanism from the NCI Drug Dictionary: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells.
Route: IV
Extravasation: no information
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 10/25/2022: Approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Based on MajesTEC-1 Phase 1 & MajesTEC-1 Phase 2)
Also known as
- Code name: JNJ 64007957
- Generic name: teclistamab-cqyv
- Brand name: Tecvayli